Table 4. Adverse events with an incidence of more than 10% in either group.
| Event | TACE group (n=98), n (%) | Non-TACE group (n=49), n (%) | |||
|---|---|---|---|---|---|
| Any grade | Grade 3–4 | Any grade | Grade 3–4 | ||
| AST/ALT increased | 55 (56.1) | 4 (4.1) | 12 (24.5) | 1 (2.0) | |
| Constipation | 35 (35.7) | 0 (0.0) | 13 (26.5) | 0 (0.0) | |
| Pyrexia | 34 (34.7) | 7 (7.1) | 14 (28.6) | 2 (4.1) | |
| Hypertension | 31 (31.6) | 9 (9.2) | 13 (26.6) | 4 (8.2) | |
| PLT decreased | 26 (26.5) | 3 (3.1) | 20 (40.9) | 2 (4.1) | |
| Fatigue | 24 (24.5) | 7 (7.1) | 15 (26.5) | 1 (2.0) | |
| Weight decreased | 24 (24.5) | 0 (0.0) | 13 (26.5) | 0 (0.0) | |
| Diarrhea | 22 (22.4) | 0 (0.0) | 7 (14.4) | 0 (0.0) | |
| Rash | 21 (21.4) | 3 (3.1) | 10 (20.4) | 1 (2.0) | |
| Pneumonitis | 13 (13.3) | 2 (2.0) | 5 (10.2) | 2 (4.1) | |
| Nausea | 11 (11.2) | 2 (2.0) | 6 (12.2) | 0 (0.0) | |
| Proteinuria | 11 (11.2) | 0 (0.0) | 6 (12.2) | 1 (2.0) | |
| TBIL increased | 10 (10.2) | 2 (2.0) | 8 (16.3) | 2 (4.1) | |
Non-TACE group refers to patients who received systemic combination therapy without TACE. AST, aspartate transaminase; ALT, alanine aminotransferase; PLT, platelet; TBIL, total bilirubin; TACE, transarterial chemoembolization.